Citation

BibTex format

@article{Sullivan:2022:ndt/gfab303,
author = {Sullivan, MK and Lees, JS and Drake, TM and Docherty, AB and Oates, G and Hardwick, HE and Russell, CD and Merson, L and Dunning, J and Nguyen-Van-Tam, JS and Openshaw, P and Harrison, EM and Baillie, JK and ISARIC4C, Investigators and Semple, MG and Ho, A and Mark, PB},
doi = {ndt/gfab303},
journal = {Nephrology Dialysis Transplantation},
pages = {271--284},
title = {Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.},
url = {http://dx.doi.org/10.1093/ndt/gfab303},
volume = {37},
year = {2022}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: Acute kidney injury (AKI) is common in coronavirus disease 2019 (COVID-19). This study investigated adults hospitalized with COVID-19 and hypothesized that risk factors for AKI would include comorbidities and non-White race. METHODS: A prospective multicentre cohort study was performed using patients admitted to 254 UK hospitals with COVID-19 between 17 January 2020 and 5 December 2020. RESULTS: Of 85 687 patients, 2198 (2.6%) received acute kidney replacement therapy (KRT). Of 41 294 patients with biochemistry data, 13 000 (31.5%) had biochemical AKI: 8562 stage 1 (65.9%), 2609 stage 2 (20.1%) and 1829 stage 3 (14.1%). The main risk factors for KRT were chronic kidney disease (CKD) [adjusted odds ratio (aOR) 3.41: 95% confidence interval 3.06-3.81], male sex (aOR 2.43: 2.18-2.71) and Black race (aOR 2.17: 1.79-2.63). The main risk factors for biochemical AKI were admission respiratory rate >30 breaths per minute (aOR 1.68: 1.56-1.81), CKD (aOR 1.66: 1.57-1.76) and Black race (aOR 1.44: 1.28-1.61). There was a gradated rise in the risk of 28-day mortality by increasing severity of AKI: stage 1 aOR 1.58 (1.49-1.67), stage 2 aOR 2.41 (2.20-2.64), stage 3 aOR 3.50 (3.14-3.91) and KRT aOR 3.06 (2.75-3.39). AKI rates peaked in April 2020 and the subsequent fall in rates could not be explained by the use of dexamethasone or remdesivir. CONCLUSIONS: AKI is common in adults hospitalized with COVID-19 and it is associated with a heightened risk of mortality. Although the rates of AKI have fallen from the early months of the pandemic, high-risk patients should have their kidney function and fluid status monitored closely.
AU - Sullivan,MK
AU - Lees,JS
AU - Drake,TM
AU - Docherty,AB
AU - Oates,G
AU - Hardwick,HE
AU - Russell,CD
AU - Merson,L
AU - Dunning,J
AU - Nguyen-Van-Tam,JS
AU - Openshaw,P
AU - Harrison,EM
AU - Baillie,JK
AU - ISARIC4C,Investigators
AU - Semple,MG
AU - Ho,A
AU - Mark,PB
DO - ndt/gfab303
EP - 284
PY - 2022///
SN - 0931-0509
SP - 271
TI - Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.
T2 - Nephrology Dialysis Transplantation
UR - http://dx.doi.org/10.1093/ndt/gfab303
UR - https://www.ncbi.nlm.nih.gov/pubmed/34661677
UR - https://academic.oup.com/ndt/article/37/2/271/6400122
VL - 37
ER -
Faculty of MedicineNational Heart and Lung Institute

General enquiries


NIHR HPRU in Respiratory Infections

Dr Victor Phillip Dahdaleh (VPD) Building
Level 5, Office 586
Imperial College London
Hammersmith Campus
Du Cane Road
London, W12 0NN

s.evetts@imperial.ac.uk